AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

Bacteria are present inside the most common type of kidney stone, revealing a previously unrecognized component involved in their formation.

The Golden Gate Assembly platform engineers bacteriophages synthetically using sequence data rather than bacteriophage isolates.

WuXi Biologics says the company will provide the partnership with integrated, end-to-end biologics development and manufacturing services.

Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.

Immune signaling in IBD triggers tumor-promoting neutrophils which is linked to an increased risk of colorectal cancer.

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.

MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

A team at Johns Hopkins Medicine has focused their work on myelin development using oligodendrocytes to help study conditions like MS.